317 related articles for article (PubMed ID: 11240975)
1. The effect of rifampin administration on the disposition of fexofenadine.
Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
[TBL] [Abstract][Full Text] [Related]
2. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
4. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
[TBL] [Abstract][Full Text] [Related]
5. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
[TBL] [Abstract][Full Text] [Related]
6. Effect of St John's wort on the pharmacokinetics of fexofenadine.
Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
[TBL] [Abstract][Full Text] [Related]
7. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment.
Olsén L; Ingvast-Larsson C; Larsson P; Broström H; Bondesson U; Sundqvist M; Tjälve H
J Vet Pharmacol Ther; 2006 Apr; 29(2):129-35. PubMed ID: 16515667
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
9. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.
Smith DA; Chandler MH; Shedlofsky SI; Wedlund PJ; Blouin RA
Br J Clin Pharmacol; 1991 Dec; 32(6):735-9. PubMed ID: 1768567
[TBL] [Abstract][Full Text] [Related]
11. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
[TBL] [Abstract][Full Text] [Related]
12. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell T; Stoltz M; Weir S
Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
[TBL] [Abstract][Full Text] [Related]
14. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Uno T; Shimizu M; Sugawara K; Tateishi T
Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
[TBL] [Abstract][Full Text] [Related]
15. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
Jin MJ; Han HK
J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
[TBL] [Abstract][Full Text] [Related]
16. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
Dilger K; Hofmann U; Klotz U
Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
[TBL] [Abstract][Full Text] [Related]
17. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
[TBL] [Abstract][Full Text] [Related]
19. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
[TBL] [Abstract][Full Text] [Related]
20. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
